{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:13:49Z","timestamp":1793056429956,"version":"4.5.0"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Postmenopausal osteoporosis increases the risk of fractures, particularly in the lumbar spine, femoral neck, and total hip. Pharmacological interventions include anabolic agents (abaloparatide [ABA], teriparatide [TER]), antiresorptive agents (oral\/intravenous bisphosphonates [OBP\/IBP], denosumab [DEN]), and conventional therapy or placebo (PLA\/CTRL). Evidence on their comparative efficacy and safety in postmenopausal women is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a Bayesian network meta-analysis of randomized controlled trials (RCTs) to evaluate the relative efficacy and safety of ABA, TER, OBP, IBP, DEN, and PLA\/CTRL in postmenopausal women with osteoporosis. Primary outcomes included changes in lumbar spine, femoral neck, and total hip bone mineral density (BMD). Safety outcomes included all adverse events (AEs) and serious adverse events (SAEs). Data were synthesized using SUCRA rankings and network consistency was assessed via node-splitting and deviance information criteria (DIC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-three RCTs comprising 80\u20137, 808 postmenopausal women were included. ABA demonstrated the greatest improvement in lumbar spine and femoral neck BMD, followed by TER, while ABA showed the highest effect on total hip BMD. IBP and DEN provided moderate benefits, superior to PLA\/CTRL. TER and OBP had the lowest risk for AEs, and ABA and PLA\/CTRL showed the lowest risk for SAEs. Overall, anabolic agents significantly improved BMD at the spine and femoral neck, whereas antiresorptive agents were more effective for hip BMD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ABA and TER are most effective for improving spinal and femoral neck BMD in postmenopausal women, whereas ABA is superior for total hip BMD. Safety profiles were favorable for TER, OBP, and ABA. These findings provide evidence to guide individualized treatment selection based on fracture risk and high-risk skeletal sites in postmenopausal women.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1886136","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T08:46:29Z","timestamp":1783586789000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of abaloparatide, denosumab, teriparatide, oral bisphosphonates, and intravenous bisphosphonates in the treatment of postmenopausal osteoporosis: a systematic review and Bayesian network meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Yan","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Orthopedics, Nanping First Hospital Affiliated to Fujian Medical University","place":["Nanping, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gynaecology and Obstetrics, Jian\u2019ou Maternal and Child Health Hospital","place":["Nanping, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihong","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Nanping First Hospital Affiliated to Fujian Medical University","place":["Nanping, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Nanping First Hospital Affiliated to Fujian Medical University","place":["Nanping, China"]},{"name":"Fujian Minbei Orthopedics Research Institute","place":["Nanping, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhui","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Nanping First Hospital Affiliated to Fujian Medical University","place":["Nanping, China"]},{"name":"Fujian Minbei Orthopedics Research Institute","place":["Nanping, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanchen","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Nanping First Hospital Affiliated to Fujian Medical University","place":["Nanping, China"]},{"name":"Fujian Minbei Orthopedics Research Institute","place":["Nanping, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiashou","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Nanping First Hospital Affiliated to Fujian Medical University","place":["Nanping, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengwu","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Nanping First Hospital Affiliated to Fujian Medical University","place":["Nanping, China"]},{"name":"Fujian Minbei Orthopedics Research Institute","place":["Nanping, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Nanping First Hospital Affiliated to Fujian Medical University","place":["Nanping, China"]},{"name":"Fujian Minbei Orthopedics Research Institute","place":["Nanping, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/jcm15010102","article-title":"Postmenopausal osteoporosis: From molecular pathways to therapeutic targets-a mechanism-to-practice framework integrating pharmacotherapy, fall prevention, and adherence into patient-centered care","volume":"15","author":"Ena","year":"2025","journal-title":"J Clin Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.ecl.2024.08.008","article-title":"Postmenopausal osteoporosis: A review of latest guidelines","volume":"53","author":"Subarajan","year":"2024","journal-title":"Endocrinol Metab Clinics North America"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2018.02.009","article-title":"2018 update of French recommendations on the management of postmenopausal osteoporosis","volume":"85","author":"Briot","year":"2018","journal-title":"Joint Bone Spine"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2174\/0113892010273783231027073117","article-title":"Insights into the mechanism of osteoporosis and the available treatment options","volume":"25","author":"Muniyasamy","year":"2024","journal-title":"Curr Pharm Biotechnol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e11880","article-title":"Efficacy and safety of pharmacologic therapies for prevention of osteoporotic vertebral fractures in postmenopausal women","volume":"9","author":"Wei","year":"2023","journal-title":"Heliyon"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234123","article-title":"Clinical efficacy and safety of drug interventions for primary and secondary prevention of osteoporotic fractures in postmenopausal women: Network meta-analysis followed by factor and cluster analysis","volume":"15","author":"Wen","year":"2020","journal-title":"PloS One"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/gme.0000000000001321","article-title":"Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: A network meta-analysis (Chongqing, China)","volume":"26","author":"Tan","year":"2019","journal-title":"Menopause (New York NY)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society* clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00192","article-title":"Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: A network meta-analysis","volume":"104","author":"Barrionuevo","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/GRF.0b013e3182a9fb02","article-title":"Osteoporosis treatment and prevention for postmenopausal women: Current and future therapeutic options","volume":"56","author":"Pinkerton","year":"2013","journal-title":"Clin Obstet Gynecol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15020673","article-title":"The efficacy and safety of abaloparatide in osteoporosis: A systematic review and meta-analysis","volume":"15","author":"Bonifacio","year":"2026","journal-title":"J Clin Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3390\/medicina62040687","article-title":"The anabolic-first strategy in osteoporosis: A systematic review and meta-analysis of fracture outcomes in patients at very high fracture risk","volume":"62","author":"Cipolloni","year":"2026","journal-title":"Med (Kaunas Lithuania)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-024-07118-0","article-title":"Denosumab vs. bisphosphonates in primary osteoporosis: A meta-analysis of comparative safety in randomized controlled trials","volume":"35","author":"Kobayashi","year":"2024","journal-title":"Osteoporos Int"},{"key":"B14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s13018-021-02497-0","article-title":"Potential of biomarkers during pharmacological therapy setting for postmenopausal osteoporosis: A systematic review","volume":"16","author":"Migliorini","year":"2021","journal-title":"J Orthopaed Surg Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1186\/s13018-021-02678-x","article-title":"Effect of drugs on bone mineral density in postmenopausal osteoporosis: A Bayesian network meta-analysis","volume":"16","author":"Migliorini","year":"2021","journal-title":"J Orthopaed Surg Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s41687-024-00727-7","article-title":"Guideline for reporting systematic reviews of outcome measurement instruments (Omis): Prisma-Cosmin for Omis 2024","volume":"8","author":"Elsman","year":"2024","journal-title":"J Patient-Report Outcomes"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1055\/a-1984-0466","article-title":"Correlation between forearm bone mineral density measured by dual energy X-ray absorptiometry and Hounsfield units value measured by CT in lumbar spine","volume":"162","author":"Pu","year":"2024","journal-title":"Z Fur Orthopad und Unfallchirurgie"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/08968608221146867","article-title":"Differences in prevalence of reduced and low bone mineral density between lumbar spine and femoral neck in peritoneal dialysis patients using dual-energy X-ray absorptiometry (DXA)","volume":"43","author":"Davenport","year":"2023","journal-title":"Peritoneal Dialysis Int"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-020-00744-w","article-title":"Effects of different types of exercise on bone mineral density in postmenopausal women: A systematic review and meta-analysis","volume":"107","author":"Kemmler","year":"2020","journal-title":"Calcif Tissue Int"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3641","article-title":"Change in bone density and reduction in fracture risk: A meta-regression of published trials","volume":"34","author":"Bouxsein","year":"2019","journal-title":"J Bone Miner Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.crtox.2020.06.001","article-title":"Development of an adverse drug event network to predict drug toxicity","volume":"1","author":"Wu","year":"2020","journal-title":"Curr Res Toxicol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-069722","article-title":"Viscosupplementation for knee osteoarthritis: Systematic review and meta-analysis","volume":"378","author":"Pereira","year":"2022","journal-title":"BMJ (Clinical Res Ed)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1446","article-title":"Efficacy, acceptability, and safety of muscle relaxants for adults with non-specific low back pain: Systematic review and meta-analysis","volume":"374","author":"Cashin","year":"2021","journal-title":"BMJ (Clinical Res Ed)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2022.08.042","article-title":"Epidemiological, methodological, and statistical characteristics of network meta-analysis in anaesthesia: A systematic review","volume":"130","author":"Sehmbi","year":"2023","journal-title":"Br J Anaesthesia"},{"key":"B26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12874-019-0829-2","article-title":"Bugsnet: An R package to facilitate the conduct and reporting of Bayesian network meta-analyses","volume":"19","author":"B\u00e9liveau","year":"2019","journal-title":"BMC Med Res Methodol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000013052","article-title":"Assessing the methodological and reporting quality of network meta-analyses in Chinese medicine","volume":"97","author":"Yang","year":"2018","journal-title":"Medicine"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1644","article-title":"Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-pivotal fracture trial (PFT)","volume":"27","author":"Jacques","year":"2012","journal-title":"J Bone Miner Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the fracture intervention trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.08.016","article-title":"Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: A 12-week, randomized, double-blind, placebo-controlled, exploratory study","volume":"31","author":"Adachi","year":"2009","journal-title":"Clin Ther"},{"key":"B32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00198-007-0485-y","article-title":"Effect of raloxifene after recombinant teriparatide [HPTH(1-34)] treatment in postmenopausal women with osteoporosis","volume":"19","author":"Adami","year":"2008","journal-title":"Osteoporos Int"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.051018","article-title":"Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: The fracture intervention trial","volume":"21","author":"Bauer","year":"2006","journal-title":"J Bone Miner Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1656955","article-title":"Abaloparatide in patients with mild or moderate renal impairment: Results from the ACTIVE phase 3 trial","volume":"35","author":"Bilezikian","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2784","article-title":"Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk","volume":"96","author":"Boonen","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-004-1602-9","article-title":"Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: Results from the BONE study","volume":"15","author":"Delmas","year":"2004","journal-title":"Osteoporos Int"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-011-1780-1","article-title":"Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: A 24-month, randomized, crossover comparison with alendronate in postmenopausal women","volume":"23","author":"Freemantle","year":"2012","journal-title":"Osteoporos Int"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral efficacy with risedronate therapy (VERT) study group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"B39","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J Bone Miner Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: A randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet (London England)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.536","article-title":"Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis","volume":"27","author":"McClung","year":"2012","journal-title":"J Bone Miner Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","author":"Miller","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B43","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","article-title":"Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study","volume":"58","author":"Roux","year":"2014","journal-title":"Bone"},{"key":"B44","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1186\/s13018-025-06083-6","article-title":"Timing optimization of teriparatide dosing for postmenopausal osteoporosis: A randomized controlled trial","volume":"20","author":"Wang","year":"2025","journal-title":"J Orthopaed Surg Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(24)00003-2","article-title":"Duration of fracture prevention after zoledronate treatment in women with osteopenia: Observational follow-up of a 6-year randomised controlled trial to 10 years","volume":"12","author":"Reid","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/jbmr\/zjaf152","article-title":"Comparative bone histomorphometry effects of combined denosumab and teriparatide vs monotherapy in postmenopausal women with osteoporosis: A randomized controlled trial","volume":"41","author":"Ramchand","year":"2026","journal-title":"J Bone Miner Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/jat.4967","article-title":"Efficacy and safety of denosumab and zoledronic acid in the treatment of postmenopausal osteoporosis-a comparative study of bone metabolism, bone density, and sex hormone levels","volume":"46","author":"Tang","year":"2026","journal-title":"J Appl Toxicol: JAT"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116416","article-title":"Randomized controlled trial of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate in patients with postmenopausal osteoporosis: The TERABIT study","volume":"160","author":"Chiba","year":"2022","journal-title":"Bone"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.clinthera.2020.04.012","article-title":"Effect of abaloparatide on bone mineral density and fracture incidence in a subset of younger postmenopausal women with osteoporosis at high risk for fracture","volume":"42","author":"Saag","year":"2020","journal-title":"Clin Ther"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1097\/gme.0000000000001080","article-title":"Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis","volume":"25","author":"McClung","year":"2018","journal-title":"Menopause (New York NY)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (Vero): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet (London England)"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3067","article-title":"Effect of teriparatide or risedronate in elderly patients with a recent pertrochanteric hip fracture: final results of a 78-week randomized clinical trial","volume":"32","author":"Malouf-Sierra","year":"2017","journal-title":"J Bone Miner Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"Jama"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.0747","article-title":"Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial","volume":"175","author":"Greenspan","year":"2015","journal-title":"JAMA Intern Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-015-3174-2","article-title":"Denosumab versus zoledronic acid in patients previously treated with zoledronic acid","volume":"26","author":"Anastasilakis","year":"2015","journal-title":"Osteoporos Int"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-011-1856-y","article-title":"The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporos Int"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2011.10.027","article-title":"Impact of oral ibandronate 150 mg once monthly on bone structure and density in post-menopausal osteoporosis or osteopenia derived from in vivo \u03bcct","volume":"50","author":"Bock","year":"2012","journal-title":"Bone"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1472","article-title":"Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures","volume":"27","author":"Austin","year":"2012","journal-title":"J Bone Miner Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2008.09.011","article-title":"Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss","volume":"44","author":"McClung","year":"2009","journal-title":"Bone"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J Bone Miner Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.09.017","article-title":"Effects of risedronate 5 mg\/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase iii trial","volume":"29","author":"V\u00e4lim\u00e4ki","year":"2007","journal-title":"Clin Ther"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Arch Internal Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.7.789","article-title":"Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial","volume":"163","author":"Ascott-Evans","year":"2003","journal-title":"Arch Internal Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020334","article-title":"A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis","volume":"87","author":"Body","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B69","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1186\/s13018-025-06040-3","article-title":"Effectiveness of anabolic and anti-resorptive agents for preventing postmenopausal osteoporosis fractures: a systematic review and network meta-analysis","volume":"20","author":"Su","year":"2025","journal-title":"J Orthopaed Surg Res"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1886136\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T08:46:31Z","timestamp":1783586791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1886136\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":69,"alternative-id":["10.3389\/fendo.2026.1886136"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1886136","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"article-number":"1886136"}}